Details of the Drug

General Information of Drug (ID: DMA5XGH)

Drug Name
Isradipine
Synonyms
Clivoten; DynaCirc; DynaCire; Dynacrine; Esradin; Icaz; Isradipin; Isradipino; Isradipinum; Isrodipine; Lomir; Prescal; Rebriden; DynaCire CR; Dynacirc CR; Isradipino [Spanish]; Isradipinum [Latin]; PN 205 033; PN 205 034; PN 205033; PN 205034; PN205033; PN205034; DynaCirc (TN); PN 200-110; PN 205-033; PN 205-034; PN-200110; Prescal (TN); Isradipine (USP/INN); Isradipine [USAN:INN:BAN]; PN-200-110; PN-205-033; PN-205-034; Isradipine, (R)-Isomer; Isradipine, (S)-Isomer; Isradipine, (+-)-Isomer; DynaCirc, Prescal, PN-200-110, Clivoten, Esradin, Isradipine; Isopropyl methyl (+-)-4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; Isopropyl 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-3-pyridinecarboxylate; Methyl 1-methylethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; O5-methyl O3-propan-2-yl 4-(2,1,3-benzoxadiazol-7-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-Isradipine; (+/-)-Isradipine; 2,1,3-Benzoxadiazole, 3,5-pyridinedicarboxylic acid deriv.; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, 3-methyl 5-(1-methylethyl) ester; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester (9CI); 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester; 3-O-methyl 5-O-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 4-(2,1,3-Benzooxadiazol-4-yl)-2.6-dimethyl-1,4-dihydro-3-isopropyloxycarbonylpyridine-5-carboxylic Acid Methyl Ester; 4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methhylethyl ester; 4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester; 4-(4-Benzofurazanyl)-1,4-dihydro-2,-6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester
Indication
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Approved [1]
Herpes simplex virus infection 1F00 Phase 3 [2]
Therapeutic Class
Antihypertensive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 371.4
Logarithm of the Partition Coefficient (xlogp) 4.3
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 26 mL/min/kg [4]
Elimination
0% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 8 hours [4]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.76928 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.04% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.5 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.008 mg/mL [3]
Chemical Identifiers
Formula
C19H21N3O5
IUPAC Name
3-O-methyl 5-O-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
Canonical SMILES
CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC
InChI
InChI=1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3
InChIKey
HMJIYCCIJYRONP-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3784
ChEBI ID
CHEBI:6073
CAS Number
75695-93-1
DrugBank ID
DB00270
TTD ID
D0Z7KE
VARIDT ID
DR00975
ACDINA ID
D00336
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calcium channel unspecific (CaC) TT5HONZ NOUNIPROTAC Modulator [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Aryl hydrocarbon receptor (AHR) OTFE4EYE AHR_HUMAN Gene/Protein Processing [7]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Gene/Protein Processing [8]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Gene/Protein Processing [7]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Gene/Protein Processing [7]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Gene/Protein Processing [9]
Cytochrome P450 2A6 (CYP2A6) OT52TWG3 CP2A6_HUMAN Gene/Protein Processing [7]
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Gene/Protein Processing [7]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Gene/Protein Processing [7]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Gene/Protein Processing [7]
Fibroblast growth factor 2 (FGF2) OT7YUJ9F FGF2_HUMAN Protein Interaction/Cellular Processes [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Isradipine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Acebutolol DM0TI4U Moderate Increased risk of cardiac depression by the combination of Isradipine and Acebutolol. Hypertension [BA00-BA04] [11]
Bisoprolol DM3UZ95 Moderate Increased risk of cardiac depression by the combination of Isradipine and Bisoprolol. Hypertension [BA00-BA04] [11]
Penbutolol DM4ES8F Moderate Increased risk of cardiac depression by the combination of Isradipine and Penbutolol. Hypertension [BA00-BA04] [11]
Nebivolol DM7F1PA Moderate Increased risk of cardiac depression by the combination of Isradipine and Nebivolol. Hypertension [BA00-BA04] [11]
Diltiazem DMAI7ZV Moderate Decreased metabolism of Isradipine caused by Diltiazem mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [12]
Pindolol DMD2NV7 Moderate Increased risk of cardiac depression by the combination of Isradipine and Pindolol. Hypertension [BA00-BA04] [11]
Labetalol DMK8U72 Moderate Increased risk of cardiac depression by the combination of Isradipine and Labetalol. Hypertension [BA00-BA04] [11]
Atenolol DMNKG1Z Moderate Increased risk of cardiac depression by the combination of Isradipine and Atenolol. Hypertension [BA00-BA04] [11]
⏷ Show the Full List of 8 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Isradipine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased metabolism of Isradipine caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [13]
Arn-509 DMT81LZ Major Increased metabolism of Isradipine caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [14]
Magnesium Sulfate DMVEK07 Moderate Additive neuromuscular blocking effects by the combination of Isradipine and Magnesium Sulfate. Acute pain [MG31] [15]
Emapalumab DMZG5WL Moderate Altered metabolism of Isradipine due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [16]
Mitotane DMU1GX0 Major Increased metabolism of Isradipine caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [14]
Siltuximab DMGEATB Moderate Altered metabolism of Isradipine due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [16]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Isradipine caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [17]
Promazine DMZAL7W Moderate Additive hypotensive effects by the combination of Isradipine and Promazine. Appearance/behaviour symptom [MB23] [18]
Voriconazole DMAOL2S Moderate Decreased metabolism of Isradipine caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [19]
Posaconazole DMUL5EW Moderate Decreased metabolism of Isradipine caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [19]
Zileuton DMVRIC2 Minor Decreased metabolism of Isradipine caused by Zileuton mediated inhibition of CYP450 enzyme. Asthma [CA23] [20]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Isradipine caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [21]
Linezolid DMGFPU2 Moderate Additive hypotensive effects by the combination of Isradipine and Linezolid. Bacterial infection [1A00-1C4Z] [22]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Isradipine caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [23]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Isradipine and Cariprazine. Bipolar disorder [6A60] [18]
Erdafitinib DMI782S Moderate Increased metabolism of Isradipine caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [24]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Isradipine caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [25]
Tucatinib DMBESUA Moderate Decreased metabolism of Isradipine caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [26]
Grepafloxacin DMGLX0T Moderate Decreased metabolism of Isradipine caused by Grepafloxacin mediated inhibition of CYP450 enzyme. Bronchitis [CA20] [27]
Sotalol DML60TN Moderate Increased risk of cardiac depression by the combination of Isradipine and Sotalol. Cardiac arrhythmia [BC9Z] [11]
Secobarbital DM14RF5 Moderate Increased metabolism of Isradipine caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [17]
Methohexital DM7YMIT Moderate Increased metabolism of Isradipine caused by Methohexital mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [17]
Thiopental DMGP8AX Moderate Increased metabolism of Isradipine caused by Thiopental mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [17]
Mifepristone DMGZQEF Moderate Decreased metabolism of Isradipine caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [28]
Pasireotide DMHM7JS Moderate Increased risk of atrioventricular block by the combination of Isradipine and Pasireotide. Cushing syndrome [5A70] [29]
Lumacaftor DMCLWDJ Major Increased metabolism of Isradipine caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [14]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Isradipine caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [30]
MK-8228 DMOB58Q Moderate Decreased metabolism of Isradipine caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [31]
Aprepitant DM053KT Moderate Decreased metabolism of Isradipine caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [32]
Fluoxetine DM3PD2C Moderate Decreased metabolism of Isradipine caused by Fluoxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [29]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Isradipine caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [33]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Isradipine and Selegiline. Depression [6A70-6A7Z] [22]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Isradipine and Isocarboxazid. Depression [6A70-6A7Z] [22]
Tranylcypromine DMGB5RE Moderate Additive hypotensive effects by the combination of Isradipine and Tranylcypromine. Depression [6A70-6A7Z] [22]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Isradipine and OPC-34712. Depression [6A70-6A7Z] [18]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Isradipine and Phenelzine. Depression [6A70-6A7Z] [22]
Primidone DM0WX6I Major Increased metabolism of Isradipine caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [14]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Isradipine caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [34]
Mephenytoin DM5UGDK Moderate Increased metabolism of Isradipine caused by Mephenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [35]
Cenobamate DM8KLU9 Moderate Increased metabolism of Isradipine caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [36]
Stiripentol DMMSDOY Moderate Decreased metabolism of Isradipine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [37]
Fosphenytoin DMOX3LB Major Increased metabolism of Isradipine caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [14]
Ethotoin DMXWOCP Moderate Increased metabolism of Isradipine caused by Ethotoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [35]
Phenobarbital DMXZOCG Major Increased metabolism of Isradipine caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [14]
Carbamazepine DMZOLBI Major Increased metabolism of Isradipine caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [38]
Timolol DM3NXRU Moderate Increased risk of cardiac depression by the combination of Isradipine and Timolol. Essential hypertension [BA00] [11]
Nadolol DMW6GVL Moderate Increased risk of cardiac depression by the combination of Isradipine and Nadolol. Essential hypertension [BA00] [11]
Tazemetostat DMWP1BH Moderate Increased metabolism of Isradipine caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [39]
Miconazole DMPMYE8 Moderate Decreased metabolism of Isradipine caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [19]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Isradipine caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [19]
Cimetidine DMH61ZB Moderate Decreased metabolism of Isradipine caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [21]
Carteolol DMFMDOB Moderate Increased risk of cardiac depression by the combination of Isradipine and Carteolol. Glaucoma [9C61] [11]
Metipranolol DMJMVKI Moderate Increased risk of cardiac depression by the combination of Isradipine and Metipranolol. Glaucoma [9C61] [40]
Levobetaxolol DMSREPX Moderate Increased risk of cardiac depression by the combination of Isradipine and Levobetaxolol. Glaucoma [9C61] [40]
Levobunolol DMTNFCQ Moderate Increased risk of cardiac depression by the combination of Isradipine and Levobunolol. Glaucoma [9C61] [40]
Carvedilol DMHTEAO Moderate Increased risk of cardiac depression by the combination of Isradipine and Carvedilol. Heart failure [BD10-BD1Z] [11]
Boceprevir DMBSHMF Moderate Decreased metabolism of Isradipine caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [41]
Simeprevir DMLUA9D Moderate Decreased clearance of Isradipine due to the transporter inhibition by Simeprevir. Hepatitis virus infection [1E50-1E51] [42]
Telaprevir DMMRV29 Moderate Decreased metabolism of Isradipine caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [41]
Rifampin DMA8J1G Major Increased metabolism of Isradipine caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [14]
Rifapentine DMCHV4I Major Increased metabolism of Isradipine caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [14]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Isradipine and Procarbazine. Hodgkin lymphoma [2B30] [22]
Delavirdine DM3NF5G Moderate Decreased metabolism of Isradipine caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [43]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Isradipine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [44]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Isradipine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [45]
Efavirenz DMC0GSJ Moderate Increased metabolism of Isradipine caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [46]
Saquinavir DMG814N Moderate Decreased metabolism of Isradipine caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [47]
Etravirine DMGV8QU Moderate Increased metabolism of Isradipine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [48]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Isradipine caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [44]
Darunavir DMN3GCH Moderate Decreased metabolism of Isradipine caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [49]
Atazanavir DMSYRBX Moderate Decreased metabolism of Isradipine caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [50]
Ritonavir DMU764S Moderate Decreased metabolism of Isradipine caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [51]
Conivaptan DM1V329 Moderate Decreased metabolism of Isradipine caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [52]
Lesinurad DMUR64T Moderate Increased metabolism of Isradipine caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [53]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Isradipine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [54]
Amobarbital DM0GQ8N Moderate Increased metabolism of Isradipine caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [17]
Pentobarbital DMFNH7L Moderate Increased metabolism of Isradipine caused by Pentobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [17]
Propiomazine DMKY8V1 Moderate Additive hypotensive effects by the combination of Isradipine and Propiomazine. Insomnia [7A00-7A0Z] [18]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Isradipine and ITI-007. Insomnia [7A00-7A0Z] [18]
PF-06463922 DMKM7EW Moderate Increased metabolism of Isradipine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [55]
Selpercatinib DMZR15V Moderate Decreased metabolism of Isradipine caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [16]
Idelalisib DM602WT Moderate Decreased metabolism of Isradipine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [56]
IPI-145 DMWA24P Moderate Decreased metabolism of Isradipine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [57]
LGX818 DMNQXV8 Moderate Increased metabolism of Isradipine caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [58]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Isradipine caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [16]
Propranolol DM79NTF Moderate Increased risk of cardiac depression by the combination of Isradipine and Propranolol. Migraine [8A80] [11]
Exjade DMHPRWG Moderate Decreased metabolism of Isradipine caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [59]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Isradipine and Thalidomide. Multiple myeloma [2A83] [28]
Siponimod DM2R86O Major Increased risk of atrioventricular block by the combination of Isradipine and Siponimod. Multiple sclerosis [8A40] [28]
Fingolimod DM5JVAN Moderate Increased risk of bradycardia by the combination of Isradipine and Fingolimod. Multiple sclerosis [8A40] [60]
Ozanimod DMT6AM2 Moderate Increased risk of bradycardia by the combination of Isradipine and Ozanimod. Multiple sclerosis [8A40] [61]
Rifabutin DM1YBHK Major Increased metabolism of Isradipine caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [14]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Isradipine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [16]
Nilotinib DM7HXWT Moderate Decreased metabolism of Isradipine caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [62]
Imatinib DM7RJXL Moderate Decreased metabolism of Isradipine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [63]
Dasatinib DMJV2EK Moderate Decreased metabolism of Isradipine caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [64]
Modafinil DMYILBE Moderate Increased metabolism of Isradipine caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [28]
Prochlorperazine DM53SRA Moderate Additive hypotensive effects by the combination of Isradipine and Prochlorperazine. Nausea/vomiting [MD90] [18]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Isradipine and Promethazine. Nausea/vomiting [MD90] [18]
Thiethylperazine DMU3IET Moderate Additive hypotensive effects by the combination of Isradipine and Thiethylperazine. Nausea/vomiting [MD90] [18]
Entrectinib DMMPTLH Moderate Decreased metabolism of Isradipine caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [65]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Isradipine caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [66]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Isradipine and Safinamide. Parkinsonism [8A00] [22]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Isradipine and Rasagiline. Parkinsonism [8A00] [22]
Abametapir DM2RX0I Moderate Decreased metabolism of Isradipine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [67]
Lefamulin DME6G97 Moderate Decreased metabolism of Isradipine caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [68]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Isradipine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [69]
Enzalutamide DMGL19D Major Increased metabolism of Isradipine caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [14]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Isradipine due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [16]
Ixekizumab DMXW92T Moderate Altered metabolism of Isradipine due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [16]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Isradipine and Levomepromazine. Psychotic disorder [6A20-6A25] [18]
Fluphenazine DMIT8LX Moderate Additive hypotensive effects by the combination of Isradipine and Fluphenazine. Psychotic disorder [6A20-6A25] [18]
Triflupromazine DMKFQJP Moderate Additive hypotensive effects by the combination of Isradipine and Triflupromazine. Psychotic disorder [6A20-6A25] [18]
Bosentan DMIOGBU Moderate Increased metabolism of Isradipine caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [70]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Isradipine and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [71]
Tocilizumab DM7J6OR Moderate Altered metabolism of Isradipine due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [16]
Canakinumab DM8HLO5 Moderate Altered metabolism of Isradipine due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [16]
Rilonacept DMGLUQS Moderate Altered metabolism of Isradipine due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [16]
Golimumab DMHZV7X Moderate Altered metabolism of Isradipine due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [16]
Sarilumab DMOGNXY Moderate Altered metabolism of Isradipine due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [16]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Isradipine and Quetiapine. Schizophrenia [6A20] [18]
Mesoridazine DM2ZGAN Moderate Additive hypotensive effects by the combination of Isradipine and Mesoridazine. Schizophrenia [6A20] [18]
Thioridazine DM35M8J Moderate Additive hypotensive effects by the combination of Isradipine and Thioridazine. Schizophrenia [6A20] [18]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Isradipine and Aripiprazole. Schizophrenia [6A20] [18]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Isradipine and Iloperidone. Schizophrenia [6A20] [18]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Isradipine and Paliperidone. Schizophrenia [6A20] [18]
Loxapine DM8AI9U Moderate Additive hypotensive effects by the combination of Isradipine and Loxapine. Schizophrenia [6A20] [18]
Haloperidol DM96SE0 Moderate Additive hypotensive effects by the combination of Isradipine and Haloperidol. Schizophrenia [6A20] [18]
Perphenazine DMA4MRX Moderate Additive hypotensive effects by the combination of Isradipine and Perphenazine. Schizophrenia [6A20] [18]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Isradipine and Molindone. Schizophrenia [6A20] [18]
Chlorpromazine DMBGZI3 Moderate Additive hypotensive effects by the combination of Isradipine and Chlorpromazine. Schizophrenia [6A20] [18]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Isradipine and Thiothixene. Schizophrenia [6A20] [18]
Clozapine DMFC71L Moderate Additive hypotensive effects by the combination of Isradipine and Clozapine. Schizophrenia [6A20] [18]
Trifluoperazine DMKBYWI Moderate Additive hypotensive effects by the combination of Isradipine and Trifluoperazine. Schizophrenia [6A20] [18]
Risperidone DMN6DXL Moderate Additive hypotensive effects by the combination of Isradipine and Risperidone. Schizophrenia [6A20] [18]
Amisulpride DMSJVAM Moderate Additive hypotensive effects by the combination of Isradipine and Amisulpride. Schizophrenia [6A20] [18]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Isradipine and Asenapine. Schizophrenia [6A20] [18]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Isradipine caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [72]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Isradipine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [16]
Larotrectinib DM26CQR Moderate Decreased metabolism of Isradipine caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [28]
Armodafinil DMGB035 Moderate Increased metabolism of Isradipine caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [28]
LEE011 DMMX75K Moderate Decreased metabolism of Isradipine caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [73]
Pitolisant DM8RFNJ Moderate Increased metabolism of Isradipine caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [16]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Isradipine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [74]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Isradipine and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [71]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Isradipine and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [71]
Methdilazine DMAUHQX Moderate Additive hypotensive effects by the combination of Isradipine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [18]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Isradipine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [75]
⏷ Show the Full List of 148 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 16 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Isradipine 5 mg capsule 5 mg Oral Capsule Oral
Isradipine 2.5 mg capsule 2.5 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4488).
2 ClinicalTrials.gov (NCT00367211) Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.. U.S. National Institutes of Health.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Optical isomers of dihydropyridine calcium channel blockers display enantiospecific effects on the expression and enzyme activities of human xenobiotics-metabolizing cytochromes P450. Toxicol Lett. 2016 Nov 16;262:173-186.
8 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
9 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
10 Proliferation of cultured human gingival fibroblasts caused by isradipine, a dihydropyridine-derivative calcium antagonist. Eur J Med Res. 2004 Jun 30;9(6):313-5.
11 Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
12 Abernethy DR, Egan JM, Dickinson TH, Carrum G "Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans." J Pharmacol Exp Ther 244 (1988): 994-9. [PMID: 3252045]
13 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
14 Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
15 Benami M, Giladi Y, Shalev E "The combination of magnesium sulphate and nifedipine - a cause of neuromuscular blockade." Br J Obstet Gynaecol 101 (1994): 262-3. [PMID: 8193107]
16 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
17 Hamann SR, Blouin RA, Chang SL, et al "Effects of hemodynamic changes on the elimination kinetics of verapamil and nifedipine." J Pharmacol Exp Ther 231 (1984): 301-5. [PMID: 6491984]
18 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
19 Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086]
20 Product Information. Zylo Filmtab (zileuton). Abbott Pharmaceutical, Abbott Park, IL.
21 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
22 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
23 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
24 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
25 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
26 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
27 Product Information. Raxar (grepafloxacin). Glaxo Wellcome, Research Triangle Park, NC.
28 Cerner Multum, Inc. "Australian Product Information.".
29 Canadian Pharmacists Association.
30 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
31 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
32 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
33 Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
34 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
35 Ahmad S "Nifedipine-phenytoin interaction." J Am Coll Cardiol 3 (1984): 1582. [PMID: 6425385]
36 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
37 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
38 Bahls FH, Ozuna J, Ritchie DE "Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin." Neurology 41 (1991): 740-2. [PMID: 2027492]
39 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
40 Henry M, Kay MM, Viccellio P "Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride." Am J Emerg Med 3 (1985): 334-6. [PMID: 2860911]
41 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
42 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
43 Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
44 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
45 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
46 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
47 Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
48 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
49 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
50 Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
51 Olkkola KT, Palkama VJ, Neuvonen PJ "Ritonavir's role in reducing fentanyl clearance and prolonging its half-life." Anesthesiology 91 (1999): 681-5. [PMID: 10485779]
52 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
53 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
54 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
55 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
56 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
57 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
58 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
59 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
60 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
61 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
62 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
63 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
64 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
65 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
66 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
67 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
68 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
69 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
70 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
71 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
72 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
73 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
74 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
75 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.